Roche receives FDA 510(k) clearance for cobas c 703 and cobas ISE neo next-generation analytical units
The cobas c 703 and cobas ISE neo analytical units deliver higher testing capacity and increased automation, helping to improve laboratory workflows and advance patient care
8 Apr 2026
cobas® c 703 analytical unit and cobas® ISE neo analytical unit
Roche has received the U.S. Food and Drug Administration (FDA) 510(k) clearance of its newest analytical units – the cobas® c 703 and cobas® ISE neo. As part of the scalable and modular cobas® pro integrated solutions, these additions deliver advanced lab automation capabilities designed to help address some of today’s most pressing laboratory challenges, including staff shortages, limited space and growing test volumes.
cobas c 703 analytical unit
The new cobas® c 703 is engineered to double the clinical chemistry throughput (internal data on file) on cobas® pro integrated solutions, delivering up to 2,000 tests per hour and 70 reagent positions. Its expanded reagent capacity enables more high-value tests to run continuously, reducing reagent reloads and improving workflow efficiency. Monthly operator maintenance further enhances uptime and productivity.
cobas ISE neo analytical unit
The cobas® ISE neo analytical unit, with up to 1,800 tests per hour, delivers more efficient ISE testing, reducing hands-on time through automated maintenance. The cobas® ISE neo system delivers more tests per reagent bottle, minimizing plastic waste and reducing logistical efforts compared to previous generation systems.
Monthly maintenance supports consistent uptime, helping laboratories manage higher volumes with fewer manual steps. Together, these units automate tasks traditionally performed manually, supporting laboratories facing staffing shortages while increasing test capacity and accelerating turnaround times.
"Laboratories are the indispensable engine of modern healthcare, and Roche wants to partner in addressing staffing shortage challenges and an ever-increasing demand for testing,” said Brad Moore, President and CEO of Roche Diagnostics North America.
“Roche is investing in solutions that help labs process more samples than ever – without sacrificing performance. The high-volume clinical chemistry and enhanced automation of the cobas® c 703 and cobas® ISE neo analytical units will streamline workflows, one test at a time."
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Related Products
Request Quote for All Products
cobas® pro integrated solutions
Experience an unprecedented level of simplicity with a scalable and modular solution to achieve your mid to high volume clinical chemistry and immunochemistry testing needs.
